Cyclic AMP is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Daniel Roy Gilchrist Noboa Azín ( noh-BOH-ə; Latin American Spanish pronunciation: [daˈnjel noˈβo.a]; born 30 November 1987) is an Ecuadorian politician and businessman serving as the 48th and current president of Ecuador since 2023. Having first taken office at the age of 35, he is the second-youngest president in the country's history, after Juan José Flores, and the youngest to be elected. Noboa was a member of the National Assembly of Ecuador from 2021 until 2023 when it was dissolved following the muerte cruzada constitutional mechanism invoked by President Guillermo Lasso. Before his political career, Noboa served in several positions at Noboa Corporation, an exporting business founded by his grandfather. Noboa's father, Álvaro Noboa Pontón, unsuccessfully ran for president of Ecuador five times. He has been widely described as an heir to his family's companies and fortune. In May 2023, Noboa announced his candidacy for president in the 2023 snap election, running on the National Democratic Action ticket. He advanced to the run-off election in October, facing Luisa González, which many interpreted as an upset given his low polling numbers in the days leading up to the election. Noboa went on to win nearly 52% of the vote in the run-off, defeating González on 15 October 2023. He was re-elected to a full four-year term in the runoff of the 2025 presidential election, defeating González again with an improved margin.
compared four sterile wound-cleansing solutions (saline, Ringer's solution, Prontosan® and Octenisept®) using a wound coating model consisting of slides containing dried blood plasma or fibrin. The concentration of dissolved proteins was measured and the findings indicate that a surfactant containing solution (polyhexamethylene biguanide with betaine) (Prontosan®) was more effective than saline in removing the protein (adhered dried plasma or fibrin). The proteins in the antiseptic solution (Octenisept®) were denatured and became insoluble. The authors suggest this implies that the antiseptic solution is unsuitable as a 'general' wound cleanser and that its use should be restricted to infected wounds. In a double-blind, randomised, stratified, controlled, parallel-group study the influence of two antiseptics (octenidine, polyhexanide) versus a placebo of Ringer's solution on wound healing in a porcine model was conducted. Assessment of healing was recorded using planimetry and histopathology. At nine days post wounding, the octenidine-treated wounds demonstrated retarded contraction at significantly greater extent than placebo and polyhexanide. At days 18 and 28 the polyhexanide treated wounds supported contraction significantly more than placebo and octenidine. The polyhexanide treated wounds led to complete wound closure after 22.9 days, in comparison to the placebo octenidine treated wounds respectively, 24.1 days (p < 0.05) and 28.3 days (no statistical difference to placebo).
In the years after Millennium, Henriksen has become an active voice actor, lending his distinctive voice to a number of animated features and video game titles. In Disney's Tarzan (1999) and its direct-to-video followup, he is Kerchak, the ape who serves as Tarzan's surrogate father. He provided the voice for the alien supervillain Brainiac in Superman: Brainiac Attacks (2006) and for the character Mulciber in Godkiller (2009). Henriksen is the voice of the character Molov in the video game Red Faction II (2002) and has also contributed to GUN (2005), Run Like Hell (2002), the canceled title Four Horsemen of the Apocalypse (2004), and the role-playing game Mass Effect (2007) as Admiral Hackett of the Human Systems Alliance. Henriksen was also the voice behind PlayStation 3's internet promotional videos. In 2005, Henriksen was the voice of Andrei Rublev in Cartoon Network's IGPX. The actor lent his voice to the animated television series Transformers: Animated as the character Lockdown. In 2009, Henriksen voiced Lieutenant General Shepherd in the award-winning game Call of Duty: Modern Warfare 2. He later provided the voice Karl Bishop Weyland in Aliens vs. Predator; also, this character's appearance resembles Henriksen's. Henriksen voiced Master Gnost-Dural in Star Wars: The Old Republic, and he also reprised his role as Admiral Hackett in Mass Effect 3. Henriksen reprised his role as Bishop in Aliens: Colonial Marines.
The United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 is one of three major drug control treaties currently in force. It provides additional legal mechanisms for enforcing the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. The Convention entered into force on November 11, 1990. As of June 2020, there are 191 Parties to the convention. These include 186 out of 193 United Nations member states (not Equatorial Guinea, Kiribati, Papua New Guinea, Solomon Islands, Somalia, South Sudan, or Tuvalu) and the Holy See, the European Union, the Cook Islands, Niue, and the State of Palestine.
Sources: en.wikipedia.org
== Safety == Dimethylformamide vapor exposure has shown reduced alcohol tolerance and skin irritation in some cases. On 20 June 2018, the Danish Environmental Protective Agency published an article about DMF's use in squishies. The density of the compound in the toy resulted in all squishies being removed from the Danish market. All squishies were recommended to be thrown out as household waste.
Epidermolysis bullosa acquisita, also known as acquired epidermolysis bullosa, is a longterm autoimmune blistering skin disease. It generally presents with fragile skin that blisters and becomes red with or without trauma. Marked scarring is left with thin skin, milia and nail changes. It typically begins around age 50. It is caused by antibodies to type VII collagen within anchoring fibril structures located at the dermoepidermal junction in skin. Damaged skin may become infected. Diagnosis is by observing the persistence of the condition, direct immunofluorescence, and detecting autoantibodies against type VII collagen. It can appear similar to porphyria cutanea tarda, pemphigoid, pemphigus, dermatitis herpetiformis, or blistering drug eruption. The condition is longterm and has no cure. A good response may be seen with corticosteroids, either alone or combined with azathioprine or dapsone. It is rare, with around 0.08 to 0.5 new cases per million people per year, and it affects males and females equally.
=== Depression === Fluoxetine is approved for the treatment of major depression in children and adults. A meta-analysis of trials in adults concluded that fluoxetine modestly outperforms placebo. Fluoxetine may be less effective than other antidepressants, but has high acceptability. For children and adolescents with moderate-to-severe depressive disorder, fluoxetine seems to be the best treatment (either with or without cognitive behavioral therapy, although fluoxetine alone does not appear to be superior to CBT alone) but more research is needed to be certain, as effect sizes are small and the existing evidence is of dubious quality. A 2022 systematic review and trial restoration of the two original blinded-control trials used to approve the use of fluoxetine in children and adolescents with depression found that both of the trials were severely flawed, and therefore did not demonstrate the safety or efficacy of the medication. In 2025, a trial restoration of the influential TADS study found that fluoxetine had not been superior to placebo in the treatment of depressed adolescents, contradicting previously reported results used in meta-analyses and guidelines.
Tividenofusp alfa, sold under the brand name Avlayah, is an enzyme replacement therapy used for the treatment of Hunter syndrome. Tividenofusp alfa is a hydrolytic lysosomal glycosaminoglycan-specific enzyme. The most common side effects include upper respiratory tract infection, ear infection, fever, anemia, cough, vomiting, diarrhea, rash, COVID-19, runny nose, nasal congestion, fall, headache, skin abrasion, and hives. Tividenofusp alfa was approved for medical use in the United States in March 2026.
Computational techniques are used to analyse high-throughput, low-measurement single cell data, such as that obtained from flow cytometry. These methods typically involve finding populations of cells that are relevant to a particular disease state or experimental condition.
Sources: en.wikipedia.org
In the field of pharmacokinetics, the area under the curve (AUC) is the definite integral of the concentration of a drug in blood plasma as a function of time (this can be done using liquid chromatography–mass spectrometry). In practice, the drug concentration is measured at certain discrete points in time and the trapezoidal rule is used to estimate AUC. In pharmacology, the area under the plot of plasma concentration of a drug versus time after dosage (called "area under the curve" or AUC) gives insight into the extent of exposure to a drug and its clearance rate from the body.
Gonadotropin surge-attenuating factor (GnSAF) is a nonsteroidal ovarian hormone produced by the granulosa cells of small antral ovarian follicles in females. GnSAF is involved in regulating the secretion of luteinizing hormone (LH) from the anterior pituitary and the ovarian cycle. During the early to mid-follicular phase of the ovarian cycle, GnSAF acts on the anterior pituitary to attenuate LH release, limiting the secretion of LH to only basal levels. At the transition between follicular and luteal phase, GnSAF bioactivity declines sufficiently to permit LH secretion above basal levels, resulting in the mid-cycle LH surge that initiates ovulation. In normally ovulating women, the LH surge only occurs when the oocyte is mature and ready for extrusion. GnSAF bioactivity is responsible for the synchronised, biphasic nature of LH secretion.
A prescription drug (also prescription medication, prescription medicine or prescription-only medication) is a pharmaceutical drug that is permitted to be dispensed only to those with a medical prescription. In contrast, over-the-counter drugs can be obtained without a prescription. The reason for this difference in substance control is the potential scope of misuse, from drug abuse to practising medicine without a license and without sufficient education. Different jurisdictions have different definitions of what constitutes a prescription drug. In North America, ℞, usually printed as "Rx", is used as an abbreviation of the word "prescription". It is a contraction of the Latin word "recipe" (an imperative form of "recipere") meaning "take". Prescription drugs are often dispensed together with a monograph (in Europe, a Patient Information Leaflet or PIL) that gives detailed information about the drug. The use of prescription drugs has been increasing since the 1960s.
As garnet starts breaking down in the later stage of metamorphism, monazite rims rich in Y and HREE will form. The extent of fractionation of Y between garnet and monazite is also found to be related to temperature. It is thus used as a thermometer, providing temperature constraints on the P-T path.
Tizanidine, sold under the brand names Zanaflex and Sirdalud among others, is an α2-adrenergic receptor agonist and muscle relaxant which is used to treat muscle spasticity due to spinal cord injury, multiple sclerosis, and spastic cerebral palsy. Its effectiveness appears to be similar to that of other muscle relaxants like baclofen or diazepam. The drug is taken orally. Common side effects of tizanidine include sleepiness, dry mouth, asthenia, dizziness, low blood pressure, and low heart rate. Serious side effects may include dangerously low blood pressure, liver problems, and psychosis. It is unclear if use in pregnancy and breastfeeding is safe. The drug is an α2-adrenergic receptor agonist, but how it works is not entirely clear. Tizanidine was approved for medical use in the United States in 1996. It is available as a generic medication. In 2023, it was the 81st most commonly prescribed medication in the United States, with more than 8 million prescriptions.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.